Management of Folliculitis Decalvans: The EADV Task Force on Hair Diseases Position Statement

    Anna Waśkiel‐Burnat, Michela Starace, Matilde Iorizzo, Alexander Katoulis, Zoé Apalla, Leila Asfour, Azael Freites‐Martínez, D. Ioannides, S. Morteza Seyed Jafari, Awatef Kelati, Francesca Pampaloni, Bianca Maria Piraccini, Adriana Rakowska, Andrea Sechi, Anita Takwale, Anastasia Therianou, Lidia Rudnicka
    TLDR Control inflammation and prevent further hair loss in folliculitis decalvans using medications and therapies.
    The management of folliculitis decalvans (FD), a chronic and relapsing form of scarring alopecia, involves a range of topical and systemic treatments aimed at controlling inflammation and preventing further hair loss. While no specific drug is approved for FD, various off-label treatments are used, including topical glucocorticosteroids, antibiotics, and systemic options like isotretinoin and hydroxychloroquine. Photodynamic therapy and biologics such as adalimumab have shown promise in refractory cases. The EADV Task Force recommends individualized treatment plans, often requiring combinations of therapies and long-term management due to the relapsing nature of FD. Diagnosis is based on clinical and trichoscopic findings, with scalp biopsy for confirmation.
    Discuss this study in the Community →

    Research cited in this study

    28 / 28 results